Last reviewed · How we verify
NCT03196024
Corazon de la Familia (Heart of the Family)
NA trial testing Family-focused intervention arm in Risk Reduction Behavior in 526 participants. Completed in 23 December 2023.
23 December 2023
Quick facts
| Lead sponsor | Gia Mudd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 526 |
| Start date | 5 October 2017 |
| Primary completion | 23 December 2023 |
| Estimated completion | 23 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Family-focused intervention arm
- Individual-focused intervention arm
Conditions studied
- Risk Reduction Behavior — all drugs for Risk Reduction Behavior →
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Gia Mudd
Who can join
18 and older, any sex, with Risk Reduction Behavior or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Corazón de la Familia study is a randomized controlled trial to examine the effects of a novel family-focused lifestyle modification intervention to reduce risk for type 2 diabetes and cardiovascular disease (CVD) among Hispanics/Latinos. Facilitated by community health workers, the family-focused intervention engages two members of a family in an educational program addressing lifestyle behaviors to support sustained engagement in healthy lifestyles among Hispanics with high risk for type 2 diabetes or CVD. In this study, we will conduct a randomized controlled trial using a 2-group design and compare the short-term and long-term impact of the family-focused active intervention to an individual-focused control condition on biological and behavioral type 2 diabetes and CVD risk factors. Furthermore, we will examine outcomes of participants in the family-focused intervention to determine how each family member's engagement in healthy lifestyle behaviors and level of support for the other family member's engagement in healthy lifestyle behaviors affects their own and their partner's outcomes.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient navigator programmes for children and adolescents with chronic diseases.
Lalji R, Koh L, Francis A, Khalid R, et al · · 2024 · cited 7× · PMID 39382077 · DOI 10.1002/14651858.cd014688.pub2 -
Experiences of ethnic discrimination and COMT rs4680 polymorphism are associated with depressive symptoms in Latinx adults at risk for cardiovascular disease.
Key KV, Estus S, Lennie TA, Linares AM, et al · · 2022 · cited 3× · PMID 35490661 · DOI 10.1016/j.hrtlng.2022.04.012
Verify or expand the search:
- PubMed search for NCT03196024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Risk Reduction Behavior
Currently open trials in the same condition.
- NCT07286955 — Life Skills Training for Soldiers Arriving at Their First Duty Location · NA · recruiting
- NCT05870878 — Generation R Next - Optimaal Opgroeien · NA · recruiting
Other Gia Mudd trials
Trials by the same sponsor.
- NCT04891575 — Heart of the Family: A Cardiovascular Disease and Type 2 Diabetes Risk Reduction Intervention in High-Risk Rural Familie · NA · completed
- NCT04096937 — Journey of Hope in Appalachia: Supporting Resilience in the Region's Youth · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03196024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gia Mudd
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03196024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing